Our pipeline of therapeutics is being developed to specifically target the causative pathological mechanisms of a number of NETs-based diseases and beyond.
Neutrolis’ unique approach allows for detailed interrogation of NET-based diseases and development of first-in-class therapeutics.
Neutrolis systematically identifies biomarkers that provide high confidence in the selection, treatment and monitoring of patients that are candidates for Neutrolis’ therapies. We leverage real-world evidence, genetics, and biomarkers to clearly define populations at a genetic and physiological level. Neutrolis uses robust detection methods to select patients likely to respond to anti-NETs therapies. In addition to patient stratification, our pharmacodynamic biomarkers also allow us to monitor treatment response to our therapies.
In patients with inflammatory or autoimmune diseases, such as lupus, NETs are formed in tissues and organs. Due to low levels of intrinsic NET disassembly, small fragments of NETs circulate in the blood.
Blood drawn and processed from patients will contain NET fragments, which are indicative of Neutrolis' drug target exposure.
Molecular biomarker analysis on NET fragments provide additional insights into treatment strategies for patients.
Neutrolis, Inc.
1 Broadway
Cambridge, MA 02142
